2021-05-21 08:40
Xintela meddelar idag att bolaget har erhållit tillstånd från Läkemedelsverket att producera cellterapiprodukter, så kallade avancerade terapiläkemedel (ATMPs), i den egna GMP-anläggningen.
2021-05-21 08:40
Xintela announces today that the company has received permission from the Medical Products Agency to produce cell therapy products, so-called advanced therapy drugs (ATMPs), in its own GMP facility.
2021-05-20 11:40
Xintela tillkännager idag att bolaget ska utveckla sin stamcellsprodukt XSTEM® för behandling av svårläkta (kroniska) sår. I samarbete med Brännskadecentrum vid Universitetssjukhuset i Linköping har Xintela i en preklinisk sårmodell visat utmärkt sårläkningsförmåga med XSTEM och planerar nu för en klinisk studie på patienter med svårläkta sår.
(0)
On April 13, 2021, the shares in Tre Kronor Property Investment AB (the Company ) were given observation status with reference to a public takeover
offer fromLSTH Svenska Handelsfastigheter AB to the shareholders in the
Company.
Today, May 4, 2021, also Trophi Fastighets AB (publ) disclosed a public
takeover offer to the shareholders in the Company.
The rules of Nasdaq First North Growth Market state that a listed company may
be given observation status if the company is subject to a public takeover
offer.
With reference to the above, Nasdaq Stockholm AB decides to update the
observation status for the shares in Tre Kronor Property Investment AB (3KR,
Minesto raises SEK 161.6m through fully subscribed warrants program
STOCKHOLM, May 4, 2021 /PRNewswire/
The warrants program TO3 in Minesto AB has been successfully completed. The program was fully subscribed, which means that Minesto adds SEK 161.6 million in proceeds before issue costs to secure the company s commercial expansion. A total of 10,236,653 new shares in Minesto were subscribed for through the warrants program, corresponding to an exercise rate of 99.1 percent. It is very satisfying that the TO3 program was fully subscribed. This contributes to a strong financial position and creates the right conditions for converting Minesto s world-leading competitive advantages in marine energy into industrial value. We are now focusing on large-scale commercial expansion together with existing and new electric utility customers and other stakeholders in renewable energy production. Continued expansion is ensured in our existing projects in the Faroe Islands and in Wales and
Nasdaq Stockholm AB: Papilly AB (publ) receives observation status (191/21)
On April 16, 2021, Papilly AB (publ) (the Company ) published a press release
with information that the Company had entered into a letter of intent to
acquire Bonzun Health Information AB.
On April 29, 2021, the Company published a press release with information that
it, because of the planned acquisition, will be subject to an examination by
Nasdaq Stockholm AB (the Exchange ) comparable to that conducted for an
entirely new issuer applying for admission to trading, after which the Exchange
will decide whether to admit the Company s shares for continued trading on
Nasdaq First North Growth Market.
Lower sales due to the pandemic but new rights issue secures continued international expansion
First quarter
Result after tax came in at SEK -8.9 (0.7) million.
Earnings per share, basic and diluted, were SEK -0.06 (0.01).
Cash and cash equivalents were SEK 21.4 (33.9) million.
Significant events in Q1
Enzymatica s sales during the quarter declined compared with the corresponding period in 2020 due to the effects of the pandemic, which essentially reduced the cold remedy market by 50 percent, both in Sweden and in other markets.
Enzymatica announced on March 22 that sales for 2021 could be lower than sales for 2020, which totaled SEK 111 million, because of the impact of the pandemic on the cold remedy market. The Board of Directors has therefore decided to raise SEK 59 million through a rights issue to fund the company s long-term initiatives and to meet working capital needs for the next 12 months.